Top-Rated StocksTop-RatedNASDAQ:GPCR Structure Therapeutics (GPCR) Stock Price, News & Analysis $44.02 +1.67 (+3.94%) (As of 09/24/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Structure Therapeutics Stock (NASDAQ:GPCR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$42.70▼$45.2250-Day Range$33.18▼$44.0252-Week Range$26.61▼$75.02Volume1.21 million shsAverage Volume794,473 shsMarket Capitalization$2.05 billionP/E RatioN/ADividend YieldN/APrice Target$88.33Consensus RatingBuy Company OverviewStructure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… You missed the class - here’s your second chance (Ad)It’s time to start your Weekend Side Hustle Right now, some of the HARDEST working folks are getting destroyed by inflation. And that’s left folks looking anywhere they can to generate extra income to cover the bills. It’s almost impossible to keep up with the ever rising costs of living anymore… Most folks think that the ONLY way to generate extra income is by picking up a second job at Costco… Or working overtime hours and late weekend nights. But with what I’m about to share…Click here and I’ll give you the details. Structure Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 48th PercentileStructure Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 613th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStructure Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Structure Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Structure Therapeutics are expected to grow in the coming year, from ($0.86) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Structure Therapeutics is -57.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Structure Therapeutics is -57.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStructure Therapeutics has a P/B Ratio of 4.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Structure Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.04% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 6.88%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldStructure Therapeutics does not currently pay a dividend.Dividend GrowthStructure Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted19.04% of the float of Structure Therapeutics has been sold short.Short Interest Ratio / Days to CoverStructure Therapeutics has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.Change versus previous monthShort interest in Structure Therapeutics has recently decreased by 6.88%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.43 News SentimentStructure Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Structure Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for GPCR on MarketBeat in the last 30 days. This is a decrease of -57% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Structure Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -29% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Structure Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.43% of the stock of Structure Therapeutics is held by insiders.Percentage Held by Institutions91.78% of the stock of Structure Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Structure Therapeutics' insider trading history. GPCR Stock News HeadlinesNovo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges (GPCR)Novo Nordisk has received both good and bad news recently when it comes to weight loss and diabetes drugs. So, where does the firm stand now?September 24 at 9:54 AM | marketbeat.comCantor Fitzgerald Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)September 24 at 3:56 PM | markets.businessinsider.com$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…September 24, 2024 | WealthPress (Ad)Morgan Stanley Initiates Coverage of Structure Therapeutics Inc. - Depositary Receipt () (GPCR) with Overweight RecommendationSeptember 24 at 3:56 PM | msn.comStructure Therapeutics (NASDAQ:GPCR) Now Covered by Analysts at Morgan StanleySeptember 24 at 5:46 AM | americanbankingnews.comStructure Therapeutics' (GPCR) "Overweight" Rating Reaffirmed at Cantor FitzgeraldSeptember 24 at 3:58 AM | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) Shares Up 7.1%September 23 at 3:27 PM | americanbankingnews.comStructure Therapeutics (NASDAQ:GPCR) Shares Gap Up to $38.75September 22 at 3:01 AM | americanbankingnews.comSee More Headlines GPCR Stock Analysis - Frequently Asked Questions How have GPCR shares performed this year? Structure Therapeutics' stock was trading at $40.76 at the beginning of 2024. Since then, GPCR shares have increased by 8.0% and is now trading at $44.02. View the best growth stocks for 2024 here. How were Structure Therapeutics' earnings last quarter? Structure Therapeutics Inc. (NASDAQ:GPCR) announced its quarterly earnings results on Thursday, August, 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.05. When did Structure Therapeutics IPO? Structure Therapeutics (GPCR) raised $150 million in an initial public offering (IPO) on Friday, February 3rd 2023. The company issued 10,740,000 shares at $13.00-$15.00 per share. Who are Structure Therapeutics' major shareholders? Structure Therapeutics' top institutional investors include Driehaus Capital Management LLC (5.53%), Federated Hermes Inc. (5.16%), Deerfield Management Company L.P. Series C (1.81%) and First Light Asset Management LLC (1.27%). How do I buy shares of Structure Therapeutics? Shares of GPCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/08/2024Today9/24/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GPCR CUSIPN/A CIK1888886 Webwww.structuretx.com Phone628-229-9277FaxN/AEmployees136Year FoundedN/APrice Target and Rating Average Stock Price Target$88.33 High Stock Price Target$118.00 Low Stock Price Target$65.00 Potential Upside/Downside+105.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($0.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-89,620,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.12% Return on Assets-19.11% Debt Debt-to-Equity RatioN/A Current Ratio41.38 Quick Ratio41.38 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$9.77 per share Price / Book4.41Miscellaneous Outstanding Shares46,619,000Free Float42,223,000Market Cap$2.01 billion OptionableOptionable Beta-3.52 This page (NASDAQ:GPCR) was last updated on 9/24/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredKamala’s tax plan is worse than you think—find out whyBuffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe $15 Stock Powering NVIDIA, TESLA and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding Structure Therapeutics Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.